Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Fasching PA, Hack CC, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Kellner S, Hofmann NM, Böhm S, Almstedt K, Lück HJ, Schmatloch S, Kalder M, Uleer C, Jurhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Hein A, Fehm TN, Häberle L.
Fasching PA, et al. Among authors: goossens c.
Eur J Cancer. 2024 Sep;209:114239. doi: 10.1016/j.ejca.2024.114239. Epub 2024 Jul 21.
Eur J Cancer. 2024.
PMID: 39059184
Free article.